STUDY OF GAMMA GLOBULIN STRUCTURE AND HYPERSENSITIVITY
STUDY OF GAMMA GLOBULIN STRUCTURE AND HYPERSENSITIVITY
批准号:
3124627
负责人:
KIMISHIGE ISHIZAKA
金额:
$22.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1974
资助国家:
美国
项目状态:
已结题
起止时间:
1974-09-01 至 1992-11-30
关键词:
DNA binding protein Escherichia coli SDS polyacrylamide gel electrophoresis T lymphocyte allergens arachidonate biological signal transduction bone marrow disorder cell differentiation cell growth regulation enzyme inhibitors gamma globulin histamine histamine release human tissue hypersensitivity immunochemistry immunoglobulin E immunoglobulin structure laboratory mouse lymphokines mast cell phosphatidylethanolamines phosphatidylinositols radioimmunoassay receptor binding tissue /cell culture
中文摘要
(改编自申请人的摘要):现已确定IgE
分子以高亲和力与肥大细胞上的Fc Delta受体结合
细胞结合的IgE抗体通过抗原交联会引发
用于释放导致过敏性疾病的介质的细胞。这个
这项研究的目的是阐明免疫学和免疫学
依赖IgE的介质释放的生化机制。以前的工作
表明细胞结合的IgE抗体分子通过
多价配体诱导磷脂酶C(PLC)活化
肌醇磷脂的水解,这一过程可能起到
在介体释放的触发信号的转导中起主要作用。
在本建议书中,i)申请人须研究-
核苷酸结合蛋白(S)参与IgE介导的激活
PLC和组胺释放。由于调查人员已经确定了
大鼠肥大细胞和骨髓来源的小鼠肥大细胞的通透性方法
细胞(BMMC),研究人员应引入非水解性GTP
类似物,如GTP伽马或GDPbetaS,进入渗透的细胞和
确定GTP类似物对抗原诱导的蛋白水解物的影响
肌醇磷脂及其介体释放。二)调查员的
最近的实验表明,一种新合成的抑制剂
磷脂酶A2抑制抗原诱导的组胺释放
和花生四烯酸从致敏的BMMC释放而不影响
肌醇磷酸盐的形成。调查人员应确认
该抑制剂不影响抗原诱导的PLC的激活,并且
确定该抑制物是否会影响与
磷脂酰肌醇周转率。调查人员预计,
实验将确定PLA2在IgE依赖中的可能作用
释放调解人。三)调查人员应努力建立文化
人嗜碱细胞选择性分化生长条件的研究
脐血细胞和骨骼中的粒细胞和肥大细胞
骨髓细胞。人T细胞或非T细胞来源的重组白介素系
将会被雇佣。成纤维细胞单层也将用于
肥大细胞的分化。四)调查人员还应继续
他们与分子生物学家合作确定了结合
人IgE分子上的Fc Delta受体与嗜碱性粒细胞上的Fc Delta受体结合。
代表小片段的重组多肽和合成多肽
将测试Delta Chain的FC部分的数据块能力
人嗜碱性粒细胞对IgE抗体的被动增敏
阻断125I标记的IgE与Fc Delta受体结合的能力
培养的人类嗜碱性粒细胞。
英文摘要
(Adapted from applicant's abstract): It has been established that IgE
molecules bind to Fc delta receptors on mast cells with high affinity, and
that cross linking of the cell bound IgE antibodies by antigen trigger the
cells for the release of mediators which cause allergic diseases. The
purpose of this research project is to elucidate the immunological and
biochemical mechanisms of IgE-dependent mediator release. Previous work
indicated that cross-linking of cell-bound IgE antibody molecules by
multivalent ligand induced activation of phospholipase C (PLC) for
hydrolysis of inositol phospholipids, and that this process may play a
major role in the transduction of triggering signals for mediator release.
In this proposal, i) the applicant shall study whether guanidine-
nucleotide binding protein(s) is involved in the IgE-mediated activation
of PLC and histamine release. As the investigators have established the
method to permeabilize rat mast cells and bone marrow-derived mouse mast
cells (BMMC), the investigators shall introduce non-hydrolyzable GTP
analogue, such as GTP gammaS or GDPbetaS, into the permeabilized cells and
determine the effect of the GTP analogue, on antigen-induced hydrolysis of
inositol phospholipids and mediator release. ii) The investigator's
recent experiment indicated that a newly synthesized inhibitor of
phospholipase A2 (PLA2) inhibited the antigen-induced histamine release
and arachidonic acid release from sensitized BMMC without affecting the
formation of inositol phosphates. The investigators shall confirm that
the inhibitor does not affect the antigen-induced activation of PLC, and
determine whether the inhibitor may affect other enzymes involved in
phosphatidylinositol turnover. The investigators expect that the
experiments will establish a possible role of PLA2 in IgE-dependent
mediator release. iii) The investigators shall try to establish culture
conditions for selective differentiation and growth of human basophil
granulocytes and mast cells from umbilical cord blood cells and bone
marrow cells. Recombinant interleukins from human T-cells or non-T-cells
will be employed. Fibroblast monolayers will also be employed for the
differentiation of mast cells. iv) The investigators shall also continue
their collaboration with molecular biologists to determine the binding
site on human IgE molecules to Fc delta receptors on basophils.
Recombinant peptides and synthetic peptides representing small segments of
the Fc portion of delta chain will be tested for the ability to block
passive sensitization of human basophils with IgE antibodies, and for the
ability to block the binding of 125 I-labeled IgE to Fc delta receptors on
cultured human basophils.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SMALL INSTRUMENTATION GRANT
-
批准号:2073648
-
项目类别:
-
资助金额:$0.89万
-
财政年份:1994
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
SMALL INSTRUMENTATION GRANT
-
批准号:3523669
-
项目类别:
-
资助金额:$0.89万
-
财政年份:1992
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
BIOMEDICAL RESEARCH SUPPORT GRANT
-
批准号:3517636
-
项目类别:
-
资助金额:$0.65万
-
财政年份:1991
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
REGULATION OF REAGINIC ANTIBODY RESPONSE
-
批准号:3124922
-
项目类别:
-
资助金额:$24.93万
-
财政年份:1990
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
ONTOGENY AND DIFFERENTIATION OF IGE-B-LYMPHOCYTES
-
批准号:2060116
-
项目类别:
-
资助金额:$19.0万
-
财政年份:1989
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
ONTOGENY AND DIFFERENTIATION OF IGE-B LYMPHOCYTES
-
批准号:3480802
-
项目类别:
-
资助金额:$15.53万
-
财政年份:1989
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
ONTOGENY AND DIFFERENTIATION OF IGE-B LYMPHOCYTES
-
批准号:3480798
-
项目类别:
-
资助金额:$16.45万
-
财政年份:1989
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
ONTOGENY AND DIFFERENTIATION OF IGE-B LYMPHOCYTES
-
批准号:3480803
-
项目类别:
-
资助金额:$18.18万
-
财政年份:1989
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
ONTOGENY AND DIFFERENTIATION OF IGE-B LYMPHOCYTES
-
批准号:3480804
-
项目类别:
-
资助金额:$18.9万
-
财政年份:1989
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
ONTOGENY AND DIFFERENTIATION OF IGE-B LYMPHOCYTES
-
批准号:3480805
-
项目类别:
-
资助金额:$4.88万
-
财政年份:1989
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
ONTOGENY AND DIFFERENTIATION OF IGE-B-LYMPHOCYTES
-
批准号:2060117
-
项目类别:
-
资助金额:$19.77万
-
财政年份:1989
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
CELLULAR & MOLECULAR MECH OF INFLAMMATORY REACTIONS
-
批准号:3531024
-
项目类别:
-
资助金额:$23.13万
-
财政年份:1982
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
CELLULAR AND MOLECULAR MECHANISMS OF IMMUNE INFLAMMATORY
-
批准号:3531022
-
项目类别:
-
资助金额:$28.23万
-
财政年份:1982
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
CELLULAR & MOLECULAR MECH OF INFLAMMATORY REACTIONS
-
批准号:3531025
-
项目类别:
-
资助金额:$32.6万
-
财政年份:1982
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
REGULATION OF REAGINIC ANTIBODY RESPONSE
-
批准号:3124920
-
项目类别:
-
资助金额:$25.86万
-
财政年份:1978
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
ONTOGENY AND DIFFERENTIATION OF IGE-B LYMPHOCYTES
-
批准号:3480797
-
项目类别:
-
资助金额:$13.13万
-
财政年份:1978
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
ONTOGENY AND DIFFERENTIATION OF IGE-B LYMPHOCYTES
-
批准号:3125885
-
项目类别:
-
资助金额:$11.68万
-
财政年份:1978
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
REGULATION OF REAGINIC ANTIBODY RESPONSE
-
批准号:3124919
-
项目类别:
-
资助金额:$22.48万
-
财政年份:1978
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
ONTOGENY AND DIFFERENTIATION OF IGE-B LYMPHOCYTES
-
批准号:3480801
-
项目类别:
-
资助金额:$8.87万
-
财政年份:1978
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
REGULATION OF REAGINIC ANTIBODY RESPONSE
-
批准号:2059771
-
项目类别:
-
资助金额:$21.89万
-
财政年份:1978
-
负责人:KIMISHIGE ISHIZAKA
-
依托单位:
国内基金
海外基金
登录
查看更多内容
asr基因调控酸诱导的Escherichia coli O157:H7形成VBNC状态的机制研究
-
批准号:32302245
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:潘寒姁
-
依托单位:
小肠中Escherichia coli分泌细菌毒素诱导肠屏障损伤及细菌易位在炎症性肠病中的机制研究
-
批准号:82371775
-
项目类别:面上项目
-
资助金额:46万元
-
批准年份:2023
-
负责人:朱慧媛
-
依托单位:
基于Escherichia coli O157:H7亚致死态细胞探究超高压与原儿茶酸协同杀菌机制
-
批准号:31871817
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2018
-
负责人:孙爱东
-
依托单位:
肠肝轴:从临床患者分离的肠道致病菌株Escherichia coli NF73-1对非酒精性脂肪性肝病的作用及机制研究
-
批准号:81873549
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2018
-
负责人:刘玉兰
-
依托单位:
高压二氧化碳诱导Escherichia coli O157:H7形成VBNC状态的分子机制
-
批准号:31571933
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:廖小军
-
依托单位:
超高压诱导牛肉中Escherichia coli O157:H7亚致死损伤及其修复研究
-
批准号:31371861
-
项目类别:面上项目
-
资助金额:15.0万元
-
批准年份:2013
-
负责人:江芸
-
依托单位:
高压二氧化碳诱导Escherichia coli O157:H7形成VBNC状态的机制
-
批准号:31371845
-
项目类别:面上项目
-
资助金额:15.0万元
-
批准年份:2013
-
负责人:廖小军
-
依托单位:
高密度二氧化碳致死Escherichia coli的相关蛋白质确证及其结构变化研究
-
批准号:31171774
-
项目类别:面上项目
-
资助金额:66.0万元
-
批准年份:2011
-
负责人:张德权
-
依托单位: